Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Prevention of Venous Thromboembolism: Elective hip replacement surgery
Age: Adult
Dose: Tablet – 2.5 mg
Frequency: twice daily
Duration: 32-38 days
Note: The initial dose should be taken 12-24 hours post-operation.
Indication: Prevention of Venous Thromboembolism: Elective knee replacement surgery
Age: Adult
Dose: Tablet – 2.5 mg
Frequency: twice daily
Duration: 10-14 days
Note: The initial dose should be taken 12-24 hours post-operation.

Child Dose

Clinical InformationAdministration Information
Indication: Treatment of venous thromboembolism and reduction in risk of recurrent venous thromboembolism
Age: Birth and older
Dose: By mouth – 0.3 mg
Frequency: twice daily
Duration: Days 1-7
Note: by mouth (oral)
Indication: Treatment of venous thromboembolism and reduction in risk of recurrent venous thromboembolism
Age: Birth and older
Dose: By mouth – 0.15 mg
Frequency: twice daily
Duration: Days 8+
Note: by mouth (oral)

Renal Dose

Clinical InformationAdministration Information
Indication: Deep Vein Thrombosis
Condition: Renal impairment, including end-stage renal disease on dialysis
Dose: Dosage Form with Dose: Not specified – Not specified
Note: No dose adjustment recommended; clinical efficacy and safety studies did not enroll patients with end-stage renal disease on dialysis or patients with a creatinine clearance less than 15 mL/min; dosing recommendations are based on pharmacokinetic and pharmacodynamic (anti-factor Xa activity) data in study subjects with end-stage renal disease maintained on dialysis
Indication: Nonvalvular atrial fibrillation
Condition: Mild-to-moderate renal impairment
Dose: Dosage Form with Dose: Not specified – Not specified
Note: No dosage adjustment required
Administration
  • Can be taken with or without food
  • Take at regular intervals
Side Effect

Drug Interaction

Drug NameRisk Factors
Strong dual CYP3A4 and P-glycoprotein (P-gp) inhibitors (e.g. clarithromycin, itraconazole, ketoconazole, ritonavir)
Increased exposure
Drugs affecting haemostasis (e.g. aspirin, heparin, fibrinolytics, SSRIs, NSAIDs (Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam, Indomethacin, Piroxicam, Ketorolac), serotonin norepinephrine reuptake inhibitors)
Increased risk of bleeding

Disease Interaction

Disease NameRisk Factors
Active Bleeding
Risk of severe hemorrhage
Hepatic Disease with Coagulopathy
Risk of bleeding complications

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.